– USA, CA – Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the elections of Steve MacMillan and Scott Ullem to its Board as Independent Directors.
Steve MacMillan will also chair the Board as Non-Executive Chairman while Scott Ullem will join the Audit Committee.
“Steve and Scott are highly respected business leaders whose public company experience and financial acumen will be very valuable to shareholders, customers and employees,” said CEO, Francis deSouza.
About Stephen P. MacMillan
Steve MacMillan joined Hologic in December 2013 as President and CEO and has led a dramatic turnaround at the Company. He was elected Chairman of the Board of Directors in June 2015. From 2005 to 2012, Mr. MacMillan served as President and CEO of Stryker, where he had been President since 2003. During his tenure at Stryker, revenues tripled from $2.8 billion to $8.3 billion. Before 2003, he was a senior executive with Pharmacia, overseeing five global businesses with revenues exceeding $2 billion, and he spent 11 years with Johnson & Johnson both in the US and Europe, including as President of the J&J-Merck joint venture.
He began his career with Procter & Gamble following a BA degree in Economics from Davidson College. He has previously served on the Boards of Directors of Alere, Boston Scientific, and Texas Instruments.
About Scott B. Ullem
Scott Ullem has been Corporate VP, and CFO, of Edwards Lifesciences since January 2014. Before joining Edwards, he served as CFO of Bemis Company Inc., a Fortune 500 publicly traded global supplier of packaging and pressure-sensitive materials used in leading food, consumer, and healthcare products. Before Bemis, Ullem spent 17 years in investment banking, serving as managing director at Goldman Sachs and later at Bank of America. He is currently a member of the board of directors of both Berry Global and egnite, as well as a Henry Crown Fellow at the Aspen Institute.
Scott Ullem received his bachelor’s degree in political science from DePauw University and his master’s degree in business administration from Harvard Business School.
About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023 we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Source: https://www.illumina.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
